Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
veliparib (ABT-888)
i
Other names:
ABT-888, ABT 888, NSC 737664, NSC-737664
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(35)
News
Trials
Company:
AbbVie
Drug class:
PARP inhibitor
Related drugs:
‹
olaparib (342)
talazoparib (81)
niraparib (80)
rucaparib (71)
pamiparib (18)
fluzoparib (11)
JPI-547 (7)
IMP4297 (6)
NOV 1401 (3)
SC10914 (2)
ABT-767 (1)
SBP-101 (1)
AMXI-5001 (0)
AZD2461 (0)
E7016 (0)
HWH340 (0)
TSL1502 (0)
[²¹¹At]PTT (0)
kt-3000 series (0)
kt-3283 (0)
SMOCL-9112 (0)
2X-121 (0)
olaparib (342)
talazoparib (81)
niraparib (80)
rucaparib (71)
pamiparib (18)
fluzoparib (11)
JPI-547 (7)
IMP4297 (6)
NOV 1401 (3)
SC10914 (2)
ABT-767 (1)
SBP-101 (1)
AMXI-5001 (0)
AZD2461 (0)
E7016 (0)
HWH340 (0)
TSL1502 (0)
[²¹¹At]PTT (0)
kt-3000 series (0)
kt-3283 (0)
SMOCL-9112 (0)
2X-121 (0)
›
Associations
(35)
News
Trials
Search handles
@Betzabe100
@GeorgeSledge51
@ShepardDale
@VivekSubbiah
@ilyassahinMD
@jamecancerdoc
@jesusanampa
@pashtoonkasi
@renata_bonadio
@tehfem
Search handles
@Betzabe100
@GeorgeSledge51
@ShepardDale
@VivekSubbiah
@ilyassahinMD
@jamecancerdoc
@jesusanampa
@pashtoonkasi
@renata_bonadio
@tehfem
Filter by
Latest
1year
T:👉 Yeni faz 2 çalışması. kemoterapiye veliparib ilacının eklenmesinin "BRCA benzeri" bir fenotipe sahip üçlü negatif meme kanserli (TNBC) hastalarda ilerleme göstermeden sağkalımı (PFS) önemli ölçüde uzatabileceğini göstermektedir.* https://t.co/AdCOmMTQFu (@ilyassahinMD)
1 year ago
BRCA (Breast cancer early onset)
|
veliparib (ABT-888)
almost2years
🙋🏻♂️Are PARP inhibitors more effective than platinum IV chemotherapy? I know of this trial @JCO_ASCO. But this was looking at the addition of PARP⛔️Veliparib to Cisplatin. @EileenMOReilly And which platinum is the best? Any clinical data in #BRCA germline? https://t.co/0ePBdolBCT (@pashtoonkasi)
almost 2 years ago
Clinical data
|
BRCA (Breast cancer early onset)
|
cisplatin • veliparib (ABT-888)
2years
Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial https://t.co/HzmQXCLOuA (@VivekSubbiah)
2 years ago
Clinical • Combination therapy
|
BRCA (Breast cancer early onset)
|
carboplatin • paclitaxel • veliparib (ABT-888)
over2years
PARP-targeted therapies in SCLC: one more - veliparib Similar or improved outcomes #SCLCchat (@LealTiciana)
over 2 years ago
PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
veliparib (ABT-888)
almost4years
Nice to see some results on the use of iPARP for BRCA-like TNBC this year. I wonder if they continued veliparib as maintenance therapy after a limited number of cisplatin cycles for pts who benefited from the therapy. (@renata_bonadio)
almost 4 years ago
Clinical
|
BRCA (Breast cancer early onset)
|
cisplatin • veliparib (ABT-888)
almost4years
SWOG S1416: Addition of veliparib to cisplatin in advanced TNBC or HER2-(BRCA1/2 mut) #BreastCancer: gBRCA1/2 group: no diff in PFS or OS BRCA-like group: improved PFS by 47%, no diff in OS non-BRCA-like group: no diff in PFS or OS #ASCO20 #oncoalert #BCSM (@jesusanampa)
almost 4 years ago
HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
cisplatin • veliparib (ABT-888)
almost4years
SWOG S1416 trial of cisplatin +/- veliparib in met TNBC and/or germline BRCA presented by Sharma. PFS endpoint in gBRCA, BRCA-like and non-BRCA-like. This was a randomized Phase 2 in the frontline setting. #ASCO20 #bcsm (@GeorgeSledge51)
almost 4 years ago
Clinical • P2 data • BRCA Biomarker • PARP Biomarker
|
BRCA (Breast cancer early onset)
|
cisplatin • veliparib (ABT-888)
almost4years
47% improvement in PFS TN #metastatic #breastcancer with #BRCA Like phenotype when veliparib was added to cisplatin @SWOG @NRGonc @ALLIANCE_org #ASCO20 @ASCO (@jamecancerdoc)
almost 4 years ago
BRCA (Breast cancer early onset)
|
cisplatin • veliparib (ABT-888)
almost4years
.@melindatelli, of @StanfordCancer, discusses data from the phase III BROCADE 3 trial, which examined the PARP inhibitor veliparib with with carboplatin and paclitaxel in patients with HER2-negative, advanced or metastatic, BRCA-mutated breast cancer #bcsm https://t.co/lXPeLR8kTF (@OncLive)
almost 4 years ago
Clinical • BRCA Biomarker • PARP Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
|
BRCA mutation
|
carboplatin • paclitaxel • veliparib (ABT-888)
almost4years
Veliparib Improves PFS in BRCA Wild-Type Ovarian Cancer, Regardless of HRD Status #ovca @SwisherLiz @SeattleCCA https://t.co/2DzCRrZCV5 (@OncLive)
almost 4 years ago
BRCA (Breast cancer early onset)
|
HRD
|
veliparib (ABT-888)
4years
Two “less is just fine” paradigms were established at #GI20: A: @skopetz @MDAndersonNews showed equivalence of doublet v triplet combos in BRAF mutant #ColonCancer B: @EileenMOReilly @sloan_kettering showed that Veliparib does not add to Gem/Cis combo in gBRCA+ #PancreaticCancer (@Aiims1742)
4 years ago
BRCA Biomarker • PARP Biomarker
|
BRAF (B-raf proto-oncogene)
|
veliparib (ABT-888)
4years
7️⃣#BRCA & PARP-inhibitors. Definitely a subset we need to identify for sure. Data from GEM/Cis+/-Veliparib. Negative but overall better outcomes. 8️⃣Anti-PD1+TKI combination trials; anxiously await more data. REGO/NIVO; REGO/PEMBRO; LEN/PEMBRO. (@pashtoonkasi)
4 years ago
BRCA (Breast cancer early onset)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • veliparib (ABT-888)
4years
Cis/Gem given to pts with advanced pancreatic cancer with gBRCA1/2 or PALB2 mutation-resulted in high response rates (>70%)and mOS (15.5 months);adding veliparib(PARP inhibitor) did not significantly improve outcomes.JCO 2020. @weoncologists @OncoAlert @EileenMOReilly @GABOUALFA (@Betzabe100)
4 years ago
Clinical • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • PALB2 (Partner and localizer of BRCA2)
|
veliparib (ABT-888)
4years
In germline BRCA/PALB2 mutations #pancreaticCa patients, Veliparib did not add benefit to CDDP/Gemcitabine combination Phase II TRIAL @EileenMOReilly @ncdhani #GI20 (@tehfem)
4 years ago
Clinical • P2 data • BRCA Biomarker • PARP Biomarker
|
PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset)
|
cisplatin • gemcitabine • veliparib (ABT-888)
4years
Phase II Trial: Gemcitabine & Cisplatin +/-Veliparib in pts With Pancreas AdenoCA and Germline BRCA/PALB2 Mutation Respose rate 74.1%(gem/cis) and 65.2% (Gem/Cis/veliparib),P=0.55 Cisplatin & gemcitabine is an effective regimen in this setting #GI20 https://t.co/IXSiDrxRF2 (@jesusanampa)
4 years ago
Clinical • BRCA Biomarker • PARP Biomarker
|
PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset)
|
cisplatin • gemcitabine • veliparib (ABT-888)
4years
Interesting phase II data at #GI20 showing a 74% RR, a PFS of 10.1 month and OS of 15.5 month for patients with met #PancreaticCancer with BRCA mutation receiving gemcitabine/cisplatin/veliparib. High heme tox and only 5% of all patients, but promising. (@ShepardDale)
4 years ago
Clinical • P2 data • BRCA Biomarker • PARP Biomarker
|
BRCA (Breast cancer early onset)
|
cisplatin • gemcitabine • veliparib (ABT-888)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login